BSA Nanoparticles Modified with N -Acetylcysteine for Improving the Stability and Mucoadhesion of Curcumin in the Gastrointestinal Tract.

Shanshan Zhang,Sajid Asghar,Feng Yu,Zhipeng Chen,Ziyi Hu,Qineng Ping,Feng Shao,Yanyu Xiao
DOI: https://doi.org/10.1021/acs.jafc.9b02272
IF: 6.1
2019-01-01
Journal of Agricultural and Food Chemistry
Abstract:A major obstacle to the clinical use of curcumin (CUR) is its reduced bioavailability because of the drug's hydrophobic nature, low intestinal absorption, and rapid metabolism. In this study, a novel oral drug delivery system was constructed for improving the stability and enhancing mucoadhesion of CUR in the gastrointestinal (GI) tract. First, CUR was encapsulated in the bovine serum albumin nanoparticles (CUR-BSA-NPs). Then, N-acetyl cysteine (NAC)-modified CUR-BSA-NPs (CUR-NBSA-NPs) were obtained. The average particle size and zeta potential of CUR-NBSA-NPs were 251.6 nm and -30.66 mV, respectively; encapsulation efficiency and drug loading were 85.79 and 10.9%, respectively. CUR-NBSA-NPs exhibited a sustained release property and prominently enhanced stability in simulated GI conditions. Additionally, enhanced mucoadhesion of CUR-NBSA-NPs was also observed. An MTT study showed that the CUR-NBSA-NPs were safe for oral administration. Overall, NAC-modified BSA-NPs may potentially serve as an oral vehicle for improving CUR stability in the GI tract and enhancing mucoadhesion.
What problem does this paper attempt to address?